Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors

Creative Commons License

Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.2, ss.111-118, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/tjh.galenos.2020.2020.0157
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.111-118
  • Anahtar Kelimeler: Acute myeloid leukemia, Measurable residual disease, Multiparameter flow cytometry, HEMATOPOIETIC-CELL TRANSPLANTATION, WORLD-HEALTH-ORGANIZATION, AML, CLASSIFICATION, NEOPLASMS, REVISION, RELAPSE
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: The optimal timing of measurable residual disease (MRD) evaluation in acute myeloid leukemia (AML) patients has not been well defined yet. We aimed to investigate the impact of MRD in pre- and post-allogeneic hematopoietic stem cell transplantation (AHSCT) periods on prognostic parameters.